John Anooshian, MD
Psychiatry · Las Vegas, NVNPI 1235189705
Payments from drug & device makers
Across 1,937 payments — averaging $431.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$345K
- Neurocrine Biosciences, Inc.$344K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$87K
- AbbVie$34K
- Alkermes, Inc.$11K
- E.r. Squibb & Sons, L.L.C.$8K
- plus $7K from 14 others
What the payments were for
- Consulting fees$46,5586%
- Speaking & faculty fees$617,32274%
- Travel & lodging$131,60916%
- Food & beverage$40,0115%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 711 | $345,402 |
| Neurocrine Biosciences, Inc. | 548 | $343,561 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 199 | $87,062 |
| AbbVie(2 entities) | 136 | $33,717 |
| Alkermes, Inc. | 78 | $10,570 |
| E.r. Squibb & Sons, L.L.C. | 38 | $7,907 |
| Sunovion Pharmaceuticals Inc. | 44 | $3,721 |
| Otsuka America Pharmaceutical, Inc. | 100 | $1,546 |
| Teva Pharmaceuticals USA, Inc. | 35 | $816 |
| Indivior Inc. | 13 | $240 |
| Lundbeck LLC | 13 | $220 |
| Janssen Scientific Affairs, LLC | 2 | $191 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
| Tris Pharma Inc | 2 | $149 |
| Axsome Therapeutics, Inc. | 6 | $126 |
| Vanda Pharmaceuticals Inc. | 7 | $123 |
| Eisai Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$334,878
- INVEGA SUSTENNA$333,248
- INVEGA TRINZA$328,643
- CAPLYTA$83,824
- VRAYLAR$31,445
- LYBALVI$29,928
- ARISTADA$6,400
- LATUDA$2,917
- ARISTADA INITIO$1,600
- UZEDY$272
- LUMRYZ$150
- Dyanavel XR$127
- LONHALA MAGNAIR$126
How this compares
$835,567 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 67 | $221,652 |
| Risperdal ConstaRisperidone Microspheres | 67 | $77,161 |
| Abilify MaintenaAripiprazole | 27 | $70,493 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $54,817 |
| VraylarCariprazine Hcl | 31 | $45,580 |
| RexultiBrexpiprazole | 16 | $23,029 |
| CaplytaLumateperone Tosylate | 12 | $18,748 |
| Clozapine | 91 | $10,660 |
| TrintellixVortioxetine Hydrobromide | 13 | $5,814 |
| Aripiprazole | 97 | $5,743 |
| Haloperidol Decanoate | 76 | $5,358 |
| Fluphenazine Hcl | 36 | $4,724 |
| Olanzapine | 195 | $4,499 |
| Asenapine Maleate | 24 | $4,442 |
| Paliperidone ErPaliperidone | 28 | $4,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $345,402 | $298,813134 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,546 | $93,52243 claims |
| Alkermes, Inc.Lybalvi | $10,570 | $54,81724 claims |
| AbbVieVraylar | $33,717 | $45,58031 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $87,062 | $18,74812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $5,81413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$12.4M
- Mustafa RawafLas Vegas$5.1M
- Aaron RitterLas Vegas$2.7M
- Sam ZandLas Vegas$410K
- Dylan WintLas Vegas$272K
- Akindele KoladeLas Vegas$79K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$18K
- Ejine OkoroaforLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.